Silver Book Fact

Cost-savings associated with Warfarin use in AFib patients

Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.

Mercaldi, CJ, M Ciaramentaro, B Hahn, G Chalissery, MW Reynolds, SD Sander, GP Samsa, and DB Matchar. Cost Efficiency of Anticoagulation with Warfarin to Prevent Stroke in Medicare Beneficiaries with Nonvalvular Atrial Fibrillation. Stroke. 2011; 42(1): 112-8. http://stroke.ahajournals.org/cgi/content/short/42/1/112

Reference

Title
Cost Efficiency of Anticoagulation with Warfarin to Prevent Stroke in Medicare Beneficiaries with Nonvalvular Atrial Fibrillation
Publication
Stroke
Publication Date
2011
Authors
Mercaldi, CJ, M Ciaramentaro, B Hahn, G Chalissery, MW Reynolds, SD Sander, GP Samsa, and DB Matchar
Volume & Issue
Volume 42, Issue 1
Pages
112-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Aspirin use in AFib patients
    Meta-analysis of a number of randomized controlled trials found that aspirin use in atrial fibrillation patients reduced stroke risk by an average 22%.  
  • Per-patient annual cost of treating stroke in atrial fibrillation patients
    The per-patient annual cost of treating stroke in atrial fibrillation patients was found to be $1,485 in a wellcontrolled anti-coagulation clinic, $3,710 for those receiving warfarin in routine medical care,…  
  • Stroke risk reduction from thrombin inhibitor in AFib patients
    A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…  
  • Effectiveness of pacemaker/defibrillators to control AFib
    Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.  
  • Stroke rates among Afib patients
    In one year, 58,283 of the 1.265 million Medicare beneficiaries with atrial fibrillation that did not receive prophylaxis suffered a stroke. For those who did receive anti-coagulants, 38,468 suffered strokes.